Ergoteles’s Legend Biotech LEGN Stock Holding History

Ergoteles’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,008	Closed	-$809K	–	1436
2021 Q3	$809K	Buy	+16,008	New	+$666K	0.03%	436

Other funds holding LEGN

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Ergoteles's LEGN Position: Q4 2021 in Review

Ergoteles sold out of Legend Biotech (LEGN) in Q4 2021, closing a stake of 16,008 shares — an estimated $809K sold.

Ergoteles first reported a position in LEGN in Q3 2021 and held it in 1 quarter. The position peaked at $809K in Q3 2021. 139 funds tracked by Wall St. Rank hold LEGN as of Q4 2021.

Ergoteles reported no remaining Legend Biotech position as of Q4 2021 after selling out during the quarter.
Ergoteles sold 16,008 Legend Biotech shares in Q4 2021, an estimated $809K.
Ergoteles first reported a position in Legend Biotech in Q3 2021 and held it in 1 quarter.
Ergoteles's Legend Biotech position peaked at $809K in Q3 2021.
139 funds tracked by Wall St. Rank held Legend Biotech as of Q4 2021.

Based on Ergoteles's 13F filing for Q4 2021, filed 14 Feb 2022.